Contineum (NASDAQ: CTNM) CSO trims stake under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain reported open-market sales of company stock. On May 1, 2026, he sold a total of 4,170 shares of Class A Common Stock in two transactions at weighted average prices of $13.06 and $13.84 per share, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 23, 2025.

After these sales, he holds 143,542 shares directly and 6,842 shares indirectly through his spouse. The prices reflect multiple trades within reported ranges between $12.69 and $13.86 per share.

Insights

CSO executes small, pre-planned stock sales and retains a large remaining stake.

The Chief Scientific Officer of Contineum Therapeutics, Daniel S. Lorrain, reported selling 4,170 shares of Class A Common Stock in open-market transactions on May 1, 2026. The weighted average prices were $13.06 and $13.84 per share across two trades.

A footnote states these transactions were carried out under a Rule 10b5-1 trading plan adopted on September 23, 2025, indicating they were pre-scheduled rather than opportunistic. Following the sales, he still directly owns 143,542 shares and indirectly holds 6,842 shares through his spouse, so the sale represents a relatively small portion of his visible holdings.

The filing also notes that the reported prices are weighted averages for multiple trades within ranges from $12.69 to $13.86. Future company filings may provide additional context on any further transactions made under this trading plan.

Insider Trade Summary 10b5-1

Net Seller: 4,170 shares ($54,694)

Net Sell 3 txns

Insider Lorrain Daniel S.

Role Chief Scientific Officer

Sold 4,170 shs ($55K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	3,870	$13.06	$51K
Sale	Class A Common Stock	300	$13.84	$4K
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 143,842 shares (Direct, null); Class A Common Stock — 6,842 shares (Indirect, By Spouse)

Footnotes (1)

These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.69 to $13.57, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.79 to $13.86, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Key Figures

Shares sold: 4,170 shares Weighted average sale price (block 1): $13.06 per share Weighted average sale price (block 2): $13.84 per share +5 more

8 metrics

Shares sold 4,170 shares Total Class A Common Stock sold on May 1, 2026

Weighted average sale price (block 1) $13.06 per share Open-market sale of 3,870 shares on May 1, 2026

Weighted average sale price (block 2) $13.84 per share Open-market sale of 300 shares on May 1, 2026

Direct holdings after sale 143,542 shares Class A Common Stock directly owned after transactions

Indirect holdings by spouse 6,842 shares Class A Common Stock held indirectly through spouse

Trading plan adoption date September 23, 2025 Rule 10b5-1 trading plan used for these sales

Price range (lower block) $12.69–$13.57 Range of prices for trades included in $13.06 average

Price range (higher block) $13.79–$13.86 Range of prices for trades included in $13.84 average

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, indirect ownership, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

""direct_or_indirect": "I", "nature_of_ownership": "By Spouse""

Form 4 regulatory

"within the ranges set forth in this footnote to this Form 4."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/01/2026 - 05:42 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lorrain Daniel S.

(Last)

(First)

(Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	05/01/2026		S⁽¹⁾		3,870	D	$13.06⁽²⁾	143,842	D
Class A Common Stock	05/01/2026		S⁽¹⁾		300	D	$13.84⁽³⁾	143,542	D
Class A Common Stock								6,842	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.69 to $13.57, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.79 to $13.86, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Remarks:

	/s/ Peter Slover, Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Contineum Therapeutics (CTNM) report for its Chief Scientific Officer?

Contineum Therapeutics reported that Chief Scientific Officer Daniel S. Lorrain sold 4,170 shares of Class A Common Stock on May 1, 2026. The sales were open-market transactions executed under a pre-arranged Rule 10b5-1 trading plan adopted in September 2025.

How many Contineum Therapeutics (CTNM) shares does the CSO still own after this Form 4?

After the reported transactions, Chief Scientific Officer Daniel S. Lorrain directly owns 143,542 shares of Contineum Therapeutics Class A Common Stock and indirectly holds 6,842 additional shares through his spouse, according to the Form 4 filing’s post-transaction ownership figures.

At what prices did the Contineum Therapeutics (CTNM) insider sell shares?

The Form 4 shows weighted average sale prices of $13.06 and $13.84 per share for the two transactions. Footnotes explain these averages reflect multiple trades in ranges between $12.69 and $13.86, with detailed trade-level data available upon request.

Was the Contineum Therapeutics (CTNM) insider sale made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted by Daniel S. Lorrain on September 23, 2025. Such pre-arranged plans automate trading, reducing the significance of short-term market timing for these sales.

How many Contineum Therapeutics (CTNM) shares did the insider sell in total?

The transaction summary reports that Daniel S. Lorrain sold a total of 4,170 shares of Contineum Therapeutics Class A Common Stock in two open-market transactions on May 1, 2026, resulting in a net-sell position for this Form 4 filing.

What does the Form 4 reveal about indirect holdings for Contineum Therapeutics (CTNM) insider Lorrain?

The Form 4 notes an indirect holding of 6,842 shares of Class A Common Stock attributed to Daniel S. Lorrain “By Spouse.” This entry reflects shares held through his spouse, separate from the 143,542 shares he owns directly in his own name.